Monday, 28 September 2026 Every NSE & BSE announcement, by company
ALFA Filings Every announcement, straight from the exchange
Financial Results · Q4 FY26

Gennex Laboratories Q4 FY26 Results: Net Profit ₹4.5 Cr, Up 45.2% YoY

Gennex Laboratories Ltd reported revenue from operations of ₹61 Cr (+51.4% YoY) and net profit of ₹4.5 Cr (+45.2% YoY) for Q4 FY26.

Q4 FY26 at a glance · ₹ crore
MetricQ4 FY26Q3 FY26Q4 FY25
Revenue from operations61.040.440.3
Other income1.32.63.8
Total income62.343.044.2
Profit before exceptional items & tax5.06.94.1
Profit before tax5.06.94.1
Net profit4.56.03.1
Operating margin8.0%16.0%9.3%

A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.

Growth
Net profit, year on year+45.20%
Net profit, quarter on quarter-25.00%
Revenue, year on year+51.40%
Source

BSE results filing, NSE: GENNEX. Figures extracted from the filing.

Read the filing ↗

Gennex Laboratories Ltd: key numbers

Share price
₹10.10
Market cap
₹245.4 Cr
Revenue (annual)
₹172.7 Cr
Net profit (annual)
₹20.98 Cr
P/E (TTM)
10.4×Sector 50.4×
Promoter holding
23.63%+0.00% QoQ
FII holding
0.00%Current quarter

Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.

More from Gennex Laboratories Ltd

All →
17:37 IST BSE
Business Update

Gennex Laboratories Business Update

Subsidiary Deccan Remedies Ltd received approvals from the Drug Control Administration, Andhra Pradesh, to manufacture ten additional pharmaceutical products and test licences at its facility.

17:40 IST BSE
Annual General Meeting

Gennex Laboratories Annual General Meeting

Gennex Laboratories Limited announced the closure of its register of members from September 23 to September 30, 2026. This is for the upcoming 41st Annual General Meeting.

17:25 IST BSE
Board Meeting Outcome

Gennex Laboratories Board Meeting Outcome

Gennex Laboratories announced the outcome of its board meeting, approving the draft directors' report and scheduling the 41st Annual General Meeting for September 30, 2026.